Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735436 · ClinicalTrials.gov registry record · Phase 2
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00735436: Clinical Trial Phase 2 study, sponsored by Duke University.
NCT00735436 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735436, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. The secondary objectives are to determine the progression-free survival following the combination of Gliadel followed by Avastin and irinotecan and to describe the toxicity of Gliadel followed by Avastin and irinotecan.
Primary Outcome
The percentage of participants surviving 24 weeks from the start of study treatment
Interventions
- DRUG Gliadel/Avastin/CPT-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Why NCT00735436 stopped before completion
NCT00735436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Gliadel/Avastin/CPT-11 is the first listed.
NCT00735436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735436 about?
NCT00735436 is a clinical study titled "A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)". The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. The secondary objectives are to determine the progression-free su...
What is the current status of trial NCT00735436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00735436?
The interventions under investigation include: Gliadel/Avastin/CPT-11 (DRUG).
Who is sponsoring clinical trial NCT00735436?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00735436's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia